Consensus Genmab A/S

Equities

GMAB

DK0010272202

Real-time Estimate Cboe Europe Other stock markets 08:21:12 2024-04-18 am EDT			5-day change	1st Jan Change
1,997 ^DKK	-0.51%		-3.15%	-7.29%

Apr. 16	Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	MT
Apr. 16	Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024	CI

Evolution of the average Target Price on Genmab A/S

Price target over the last 5 years

History of analyst recommendation changes

06c2dcc090dd.a8dqD7zHncWef2AbdC20yqyGU4iG6g4amE2LhxG9o54.D_UCYtGU_JrfOzAjEl7Tq-_wP8y-s2NMwiHUv0fSmvMJhEdY6KrbvPEOVA~57ce80de300723d1e84a8c6dfb102ee6

Analyst Recommendations on Genmab A/S

GENMAB : Genmab is available at a bargain price	Mar. 04
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46	Feb. 23	MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating	Feb. 21	MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks	Feb. 15
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating	Jan. 29	MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating	Nov. 09	MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating	Nov. 08	MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded	Nov. 08
GENMAB : Factoring in some caution	23-10-31
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating	23-10-13	MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact	23-08-25
BTIG Starts Genmab at Buy With $44 Price Target	23-08-24	MT
GENMAB : A good Q2 + improved sales guidance	23-08-04
AbbVie, Genmab Say Phase 1/2 Trial of Epcoritamab in Follicular Lymphoma Patients Showed 82% of Overall Response Rate	23-06-28	MT
Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma	23-06-09	MT
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating	23-05-22	MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	23-05-16	MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss	23-05-11
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry	23-03-20
HC Wainwright Adjusts Price Target on Genmab to $46 From $51, Maintains Buy Rating	23-03-02	MT
Morgan Stanley Trims Price Target on Genmab to $33 From $34, Maintains Underweight Rating	23-03-01	MT
GENMAB : Promising 2022; even softer 2023 guidance isn’t a worry	23-02-23
Morgan Stanley Adjusts Price Target on Genmab to $34 From $35, Keeps Underweight Rating	23-02-23	MT
SVB Securities Adjusts Price Target on Genmab A/S to $36 From $33, Maintains Market Perform Rating	23-02-06	MT
AbbVie Says Epcoritamab Shows Overall Response Rate of Between 60% and 95% in Lymphoma, Richter's Syndrome Trials	22-12-12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,007 DKK

Average target price

2,434 DKK

Spread / Average Target

+21.28%

High Price Target

3,190 DKK

Spread / Highest target

+58.94%

Low Price Target

1,662 DKK

Spread / Lowest Target

-17.19%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genmab A/S

alphavalue	Anas Patel
BMO Capital
RBC Capital Markets
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
William Blair & Co.
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar